These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12411296)

  • 21. Nucleoside transporters in chronic lymphocytic leukaemia.
    Pastor-Anglada M; Molina-Arcas M; Casado FJ; Bellosillo B; Colomer D; Gil J
    Leukemia; 2004 Mar; 18(3):385-93. PubMed ID: 14737075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
    Moufarij MA; Sampath D; Keating MJ; Plunkett W
    Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
    Johnston JB; Paul JT; Neufeld NJ; Haney N; Kropp DM; Hu X; Cheang M; Gibson SB
    Leuk Lymphoma; 2004 Oct; 45(10):2017-27. PubMed ID: 15370246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
    Martinez-Lostao L; Briones J; Martinez-Gallo M; Forné I; Sierra J; Rodriguez-Sanchez JL; Juarez C
    Leuk Lymphoma; 2004 Nov; 45(11):2307-14. PubMed ID: 15512822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
    Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
    Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
    Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
    Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
    Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
    Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
    Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
    PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
    de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
    Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
    King KM; Damaraju VL; Vickers MF; Yao SY; Lang T; Tackaberry TE; Mowles DA; Ng AM; Young JD; Cass CE
    Mol Pharmacol; 2006 Jan; 69(1):346-53. PubMed ID: 16234483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
    Frezzato F; Gattazzo C; Martini V; Trimarco V; Teramo A; Carraro S; Cabrelle A; Ave E; Facco M; Zambello R; Tibaldi E; Brunati AM; Semenzato G; Trentin L
    PLoS One; 2012; 7(6):e39902. PubMed ID: 22768161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equilibrative Nucleoside Transporter 1 (ENT1,
    Cerveny L; Ptackova Z; Ceckova M; Karahoda R; Karbanova S; Jiraskova L; Greenwood SL; Glazier JD; Staud F
    Drug Metab Dispos; 2018 Nov; 46(11):1817-1826. PubMed ID: 30097436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.
    Fotoohi AK; Lindqvist M; Peterson C; Albertioni F
    Biochem Biophys Res Commun; 2006 Apr; 343(1):208-15. PubMed ID: 16530731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
    Pettitt AR; Sherrington PD; Cawley JC
    Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
    Petersen AJ; Brown RD; Gibson J; Pope B; Luo XF; Schutz L; Wiley JS; Joshua DE
    Eur J Haematol; 1996 Apr; 56(4):213-20. PubMed ID: 8641389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.
    Fernández-Calotti P; Pastor-Anglada M
    J Biol Chem; 2010 Apr; 285(18):13589-98. PubMed ID: 20172853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
    Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
    Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
    Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.